Published in AIDS Res Hum Retroviruses on March 01, 2000
Close phylogenetic relationship between Angolan and Romanian HIV-1 subtype F1 isolates. Retrovirology (2009) 1.11
Using phylogeography to characterize the origins of the HIV-1 subtype F epidemic in Romania. Infect Genet Evol (2011) 1.07
Near full-length genome analysis of low prevalent human immunodeficiency virus type 1 subclade F1 in São Paulo, Brazil. Virol J (2009) 0.88
Determination of human immunodeficiency virus type 1 subtypes by a rapid method useful for the routine diagnostic laboratory. Clin Diagn Lab Immunol (2001) 0.83
Molecular typing of the recently expanding subtype B HIV-1 epidemic in Romania: evidence for local spread among MSMs in Bucharest area. Infect Genet Evol (2012) 0.80
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
Antigenic diversity thresholds and the development of AIDS. Science (1991) 5.13
Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes. J Virol (1991) 5.03
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology (1992) 4.70
Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet (1986) 4.54
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol (1992) 4.39
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
Characterization of HIV-1 neutralization escape mutants. AIDS (1989) 3.88
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest (1988) 3.59
Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS (1988) 3.50
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol (1990) 3.35
HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology (1991) 3.33
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) (1986) 3.27
Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. BMJ (1989) 3.16
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci U S A (1990) 2.78
Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes. Virology (1992) 2.76
Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed) (1986) 2.75
Antibody response in primary human immunodeficiency virus infection. Lancet (1987) 2.69
Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology (1991) 2.59
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 2.50
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol (1992) 2.41
Neutralization of HIV-1: a paradox of humoral proportions. FASEB J (1991) 2.41
Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS (2001) 2.41
Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet (1988) 2.38
Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol (1987) 2.32
Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS (1998) 2.19
Universal cellular tropism? Nature (1992) 2.18
Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. J Infect Dis (1987) 2.17
Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. The UNAIDS Network for HIV Isolation and Characterization. J Virol (1996) 2.17
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology (1994) 2.15
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover. Science (1996) 2.12
Susceptibility to infection by the human immunodeficiency virus (HIV) correlates with T4 expression in a parental monocytoid cell line and its subclones. Virology (1987) 2.11
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 2.09
Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics (1986) 2.09
Impact of HIV antibody testing on changes in sexual behavior among homosexual men in The Netherlands. Am J Public Health (1988) 2.07
N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem (2001) 2.07
Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis (1988) 2.06
Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis (1990) 2.06
Alternative view on AIDS. Lancet (1992) 2.06
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol (1995) 2.06
Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. Am J Epidemiol (2000) 2.05
The role of BK virus in acute respiratory tract disease and the presence of BKV DNA in tonsils. J Med Virol (1982) 2.04
Post-transcriptional cosuppression of beta-1,3-glucanase genes does not affect accumulation of transgene nuclear mRNA. Plant Cell (1995) 2.03
Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed) (1987) 2.02
Infection of brain-derived cells with the human immunodeficiency virus. J Virol (1987) 2.01
Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.99
Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses. J Virol (2001) 1.98
AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS (1997) 1.97
HIV infection and STD in drug addicted prostitutes in Amsterdam: potential for heterosexual HIV transmission. Genitourin Med (1989) 1.88
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology (1994) 1.85
Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology (1991) 1.85
Ongoing HIV dissemination during HAART. Nat Med (1999) 1.85
Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS (1993) 1.85
Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS (1989) 1.83
Structural and rheological properties of methacrylamide modified gelatin hydrogels. Biomacromolecules (2000) 1.82
Improved silica-guanidiniumthiocyanate DNA isolation procedure based on selective binding of bovine alpha-casein to silica particles. J Clin Microbiol (1999) 1.81
Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol (2001) 1.79
Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, coinfection, and recombinants of HIV-1 subtypes A and C. Virology (1997) 1.79
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol (1997) 1.77
Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. Proc Natl Acad Sci U S A (1993) 1.77
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity. Eur J Immunol (1991) 1.72
Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol (1993) 1.70
Detecting dinosaur DNA. Science (1995) 1.69
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2000) 1.68
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 1.66
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS (1999) 1.64
HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS (1999) 1.55
Independent fluctuation of human immunodeficiency virus type 1 rev and gp41 quasispecies in vivo. J Virol (1991) 1.55
First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine (2008) 1.51
The 3' untranslated region of satellite tobacco necrosis virus RNA stimulates translation in vitro. Mol Cell Biol (1993) 1.50
Expression of RNA and antigens of human immunodeficiency virus type-1 (HIV-1) in lymph nodes from HIV-1 infected individuals. Am J Pathol (1988) 1.48
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS (1992) 1.47
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection. AIDS (2000) 1.47
Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol (1993) 1.45
Baboon endogenous virus evolution and ecology. Trends Microbiol (1996) 1.44
Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS (1993) 1.44
Two distinct gamma-2 herpesviruses in African green monkeys: a second gamma-2 herpesvirus lineage among old world primates? J Virol (2000) 1.44
Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun (2006) 1.43
Efficacy of the latest generation of antibody assays for (early) detection of HIV 1 and HIV 2 infection. Vox Sang (1989) 1.43
Viral gene expression, antibody production and immune complex formation in human immunodeficiency virus infection. AIDS (1987) 1.43
Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS (1998) 1.42
Genomic human immunodeficiency virus type 1 RNA variation in mother and child following intra-uterine virus transmission. J Gen Virol (1993) 1.42
Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity. J Gen Virol (1989) 1.41
Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol (1994) 1.41